Exosomes

What it is

Exosomes are extracellular vesicles 40 to 160 nanometers in diameter, released from the endosomal compartment of cells. They carry nucleic acids, lipids, proteins, and signaling metabolites between cells. In aesthetic dermatology, the dominant Korean product is ExoCoBio's ASCE+, derived from human adipose tissue mesenchymal stem cells using the company's proprietary ExoSCRT process, a tangential flow filtration method with a 500 kDa cutoff membrane that isolates vesicles in the 40 to 160 nm range.

ExoCoBio's products are registered as cosmetics in Korea, the United States, and the European Union. They are not classified as drugs or medical devices in any major jurisdiction. In Korean clinics, ASCE+ is typically applied topically to the skin immediately after micro-channels are created via microneedling, fractional laser, or another ablative device. Korean clinical literature refers to this practice as drug delivery after fractional procedures.

ExoCoBio (엑소코바이오) is a Seoul-based company that reported 2024 consolidated revenue of approximately 95.4 billion KRW with operating profit near 20 billion KRW. The company won the 11th IR52 Jang Young-sil Prize (장영실상) in 2020, a major Korean science and technology award, for its ASC-exosome technology.

How it works

Exosomes from adipose stem cells carry growth factors, microRNAs, lipids, and signaling proteins. In published mechanism studies these contents have been shown to drive fibroblast proliferation and collagen production, modulate inflammation by reducing IL-4, IL-5, IL-13, TNF-alpha, IFN-gamma, and TSLP, restore the epidermal barrier through de novo ceramide synthesis and lamellar body formation, suppress melanogenesis, and support angiogenesis and wound healing through the VEGF and ERK/PI3K/AKT pathways.

A 2023 split-face randomized controlled trial by Park and colleagues, with 28 participants, compared adipose stem cell exosome solution plus microneedling against microneedling alone. At 12 weeks the exosome side showed a 13.4 percent reduction in wrinkles versus 7.1 percent on the control side (p = 0.007), an 11.3 percent increase in skin elasticity versus a 3.3 percent decrease (p = 0.002), a 6.5 percent increase in hydration (p = 0.037), and a 9.9 percent decrease in melanin (p = 0.044). A 2020 split-face study by Kwon and colleagues, with 25 participants, used adipose stem cell exosomes after fractional CO2 laser for acne scars and reported 32.5 percent improvement in the Acne Scar Assessment Scale versus 19.9 percent with laser alone, with shorter post-treatment downtime.

Korea's MFDS published the world's first guideline for extracellular vesicle therapy products, establishing Korea as the first regulatory jurisdiction with a defined framework for therapeutic exosomes.

Origin and development

ExoCoBio was incorporated in Seoul and developed the ExoSCRT technology under Korean patent 10-1895916. The product line grew alongside Korea's broader stem cell biotech sector. ExoCoBio has presented at ASLS 2024, KOREADERMA 2024, and the RAES 2025 global exosome summit.

A regulatory tightening then followed the market boom. Effective January 2025, MFDS updated cosmetic labeling and advertising rules to prohibit the term "exosome" in cosmetic advertising, citing consumer confusion between cosmetic-classified products and medical treatments. Korean clinics that advertised "엑소좀 주사" (exosome injection) as a standalone medical injectable, rather than as a topical cosmetic applied after microneedling, were operating outside regulatory boundaries. A widely shared Korean medical professional video from 2023 explicitly stated that injecting cosmetic-classified exosome products is illegal (불법) in Korea.

Regulatory status

The pattern across all three jurisdictions is consistent: topical post-procedure application is the only legitimate cosmetic use of currently available products. Any clinic offering exosome injection as a medical treatment is operating outside the cleared classification of the products on the market.

Typical protocol

Standard Korean clinic protocol uses topical application after microneedling with a roller or motorized pen.

• Sessions: 3 to 4 per course
• Interval: 2 to 4 weeks between sessions
• Session duration: 30 to 45 minutes including microneedling plus exosome application
• Anesthesia: topical numbing cream applied 20 to 30 minutes prior
• Downtime: redness for 12 to 48 hours
• Visible improvement: typically 5 to 7 days
• Full collagen remodeling: 4 to 6 weeks
• Post-care: avoid harsh skincare and exfoliation for one week, daily SPF

The exosome solution is applied to the skin surface after micro-channels have been created. The mechanism relies on the channels providing an entry path for the topical product during the brief window before the skin barrier reseals.

Commonly reported effects

• Topical post-procedure use. From the Park et al. 2023 RCT, the Global Aesthetic Improvement Scale score was significantly higher in exosome-treated skin at six weeks (p = 0.023) and twelve weeks (p = 0.005), with measurable gains in wrinkle depth, elasticity, hydration, and melanin. ExoCoBio pre-clinical data confirmed dose-dependent reductions in transepidermal water loss and pro-inflammatory cytokines in inflammatory skin models. No significant adverse events have been reported for topical ASCE+ application in published clinical studies.
• Injectable use carries documented harm. FDA-documented serious adverse events from unapproved injectable exosome products include bacterial infections. The Liveyon prosecution documented 19 patients in 8 US states hospitalized for bacterial infections from cell-based injectable products. The perpetrator was sentenced to 36 months federal prison. The case illustrates contamination risk from any injectable exosome product manufactured without validated sterility controls.

The published evidence base supports topical use after fractional procedures. There is no comparable clinical evidence base for injection of cosmetic-classified exosome products, which is also outside their approved use across all major jurisdictions.

Korea vs US availability

ExoCoBio ASCE+ SRLV is available through Korean clinic wholesale channels, with wholesale pricing reflecting the product's cosmetic classification and global export demand. Per 모두닥 (Modoodoc) 2026 platform data, a 3 cc session in Seoul ranges from approximately ₩220,000, and a 6 cc session from approximately ₩495,000.

In the United States, exosome facials are widely offered as post-procedure topical treatments with reported pricing variably between approximately $500 and $3,500 per session depending on provider, combination protocol, and brand. The wide range reflects the lack of standardized cosmetic positioning across US clinics.

International clients seek exosome treatments in Korea for two reasons. First, Korean clinics have built extensive procedural fluency in combining ASCE+ with microneedling and laser. Second, Korean retail pricing for the same product is materially lower than typical US pricing.

What to research before

Before booking exosome treatment in Korea:

• Confirm topical, not injection. Cosmetic-classified exosomes are legitimately applied topically after microneedling or laser. Injection of these products is outside their cleared classification in Korea, the US, and the EU. A clinic offering "exosome injection" as a standalone medical treatment is offering something with no approved-product basis.
• Verify the brand and source. ExoCoBio's ASCE+ is the most studied Korean exosome cosmetic. Other brands exist with much thinner published evidence. Ask for the product name and request to see the original packaging at the appointment.
• Verify the clinic and the operator. Our credential verification guide covers KSPRS and specialty registries.
• Be skeptical of "FDA-approved" claims. No injectable exosome product is FDA-approved for any therapeutic use. Topical use of a US-cosmetic-registered product is the limit of US legality.
• Understand what the procedure is and is not. Topical exosome application after microneedling is a delivery-enhancement step that adds incremental improvement to the underlying microneedling protocol. It is not a standalone treatment with the same volumetric or structural effect as fillers, biostimulators, or energy devices.
• See also: our Korean Surgery Safety Guide and red flags guide.

Related procedures

• Rejuran — Korean polynucleotide injectable; injectable medical device, not cosmetic
• Juvelook — Korean PDLLA biostimulator injectable
• Microneedling (MTS) — the carrier procedure that creates the channels for topical exosome application
• Fractional CO2 laser — alternative carrier procedure for post-laser exosome application
• Skin boosters — umbrella category of injectable hydration and regeneration products

Sources

1. Bai F et al. Clinical applications of exosomes in cosmetic dermatology. JEADV Skin Health and Disease 2024. https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.348
2. Shin KO et al. (ExoCoBio). Exosomes from Human Adipose Tissue-Derived MSCs Promote Epidermal Barrier Repair. Cells 2020;9(3):680. https://pmc.ncbi.nlm.nih.gov/articles/PMC7140723/
3. ASCE+ ExoCoBio brand page. https://www.asceplus.com/Brand
4. GPC Gateway. South Korea Expands Prohibited Expressions in Cosmetic Labelling 2025. https://gpcgateway.com/regulatory-regions/south-korea/news-detail/south-korea-expands-prohibited-expressions-in-cosmetic-labelling-and-advertising-new-regulations-effective-2025-MTc4MA==
5. 위키트리/바비톡 (Wikitree/Babitalk). 2025 S/S trend report (ExoCoBio financial data). https://www.wikitree.co.kr/articles/1037057
6. Choijilsuren G et al. MSC-Derived Exosomes for Regenerative Medicine. Cells 2020;9(5):1237. https://pmc.ncbi.nlm.nih.gov/articles/PMC7290908/
7. Korean dermatologist video, 2023. 엑소좀, 샤넬주사 불법 스킨부스터는 왜 시술하면 안되는걸까? https://www.youtube.com/watch?v=0g3wGMcrp8k
8. FDA. Public Safety Notification on Exosome Products. December 6, 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products
9. Armstrong & Bradylyons PLLC. FDA Warning Letters on Exosome Products. https://www.armstrongbradylyons.com/library/fda-warning-letters-exosome-product
10. 모두닥 (Modoodoc), 엑소좀 ASCE+ 가격정보 2026. https://www.modoodoc.com/blog/price-detail